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TABLE OF CONTENTS/ABSTRACT: 
4,5-Diazaspiro[2.3]hexanes are made by dihalocarbene addition across the exocyclic double bond of 
readily accessible 3-alkylidene-1,2-diazetidines. Using difluorocarbene, generated from TMSCF3/NaI, 
these spirocycles were produced in yields up to 97% by stereospecific addition across the alkene.  
Lower yields (up to 64%) were observed using more reactive dichlorocarbene, due to competitive 
insertion of the carbene into the N–N bond.  Larger 1,2-diazaspiro[3.3]heptanes are produced by [2+2] 
cycloaddition of 3-alkylidene-1,2-diazetidines with tetracyanoethylene (TCNE) in up to 99% yield.  
Spirocyclic heterocycles are emerging as valuable tools in medicinal chemistry,1,2 with those containing 
a four-membered ring being of prominent interest.3 In general, spirocycles have a number of properties 
beneficial to medicinal chemistry programs including their inherent rigidity, structural novelty, reduced 
lipophilicity and potential to place attached functional groups precisely in three-dimensional space. 
Through the development of chemistry of new heterocyclic systems, there is scope to create novel 
spirocyclic scaffolds that can open up uncharted regions of chemical space for drug discovery. In this 
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Note, we report efficient methods for the functionalization of the exocyclic double bond of 3-
alkylidene-1,2-diazetidines, providing entry to 4,5-diazaspiro[2.3]hexanes and 1,2-
diazaspiro[3.3]heptanes as potential hexahydropyridazine analogues.  
The pyridazine nucleus containing two adjacent nitrogen atoms within a six-membered ring is a 
privileged substructure in medicinal chemistry.4 An important member of this group is the saturated 
hexahydropyridazine nucleus, with a number of molecules including actinoramide A,5 cilazapril,6 and 1-
azafagomine7 possessing prominent bioactivity (Figure 1a).  Since introduction of a spirocenter into 
other saturated nitrogen heterocycles has proved valuable,1,2 we reasoned that rigidification of the 
hexahydropyridazine nucleus might have considerable merit.  With this in mind, we targeted the 
synthesis of 4,5-diazaspiro[2.3]hexanes and 1,2-diazaspiro[3.3]heptanes as analogues of the 
hexahydropyridazine nucleus (Figure 1b). Our planned approach to these frameworks was to exploit 
carbene additions (n = 0) and [2+2] cycloadditions (n = 1) of readily accessible 3-methylene-1,2-
diazetidines.8-10 At the outset of this study, very little was known about the reactivity of these 
unsaturated heterocycles.8,10-12 Iacobini et al. have reported Rh-catalyzed asymmetric hydrogenations 
producing 3-alkyl-1,2-diazetidines in up to 89% ee.11 Brown et al. have described Pd-catalyzed Heck 
reactions as a way to introduce additional substituents on the exocyclic double bond.8  Very recently, 
Okitsu et al. have reported nucleophilic ring opening of 3-methylene-4-amido-1,2-diazetidines with silyl 
enol ethers and allyltrimethylsilanes.10
Figure 1. (a) Illustrative bioactive molecules containing the hexahydropyridazine nucleus. (b) 
Planned strategy to 4,5-diazaspiro[2.3]hexanes (n = 0) and 1,2-diazaspiro[3.3]heptanes (n = 1) and 
their potential use as rigidified hexahydropyridazine analogues.   
A series of 3-alkylidene-1,2-diazetidines 2a-g was made to explore this chemistry.  They were 
conveniently made by copper catalyzed ring closure of the corresponding 2-bromo-2-propenyl 
hydrazines 1a-g in the presence of N,N’-dimethylethylenediamine (DMEDA) and cesium carbonate 
(Scheme 1).8 The synthesis of the requisite precursors 1a-g was straightforward (see Experimental 
Section). The Cu-catalyzed ring closure is known to proceed with net stereochemical retention at the 
vinylic carbon.8 Thus, (Z)-2d was produced from (Z)-1d as a single geometric isomer. Of further note, 
the synthesis of 2g provides the first example of a 3-alkylidene-1,2-diazetidine bearing different groups 
on the two nitrogen atoms allowing selective deprotection/functionalization of the heteroatoms. Finally, 
2h bearing a benzyl ester on the double bond was produced from benzyl allenoate and di-tert-butyl 
azodicarboxylate according to the method of Xu.9
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Scheme 1. Copper catalyzed ring closure to 3-alkylidene-1,2-diazetidines 2a-g. 
With 2a-h in hand, we first explored the addition of carbenes to the exocyclic double bond of these 
heterocycles.  Preliminary experiments indicated that dihalocarbenes possess the correct balance of 
reactivity/stability for this transformation.13 Our first success came with the synthesis of 4,5-
diazaspiro[2.3]hexane 3 by way of difluorocarbene14 addition to 3-alkylidene-1,2-diazetidine 2.  
Treatment of bis-Boc 2c with the Ruppert-Prakash reagent TMSCF3 and NaI according to the method of 
Wang15 provided 3a in essentially quantitative yield (Scheme 2). The structure of this product was 
unambiguously established by single-crystal X-ray diffraction. In the solid-state, the two nitrogen atoms 
display highly pyramidal geometries with the Boc groups projecting on opposite faces of the four 
membered ring (Scheme 2). The introduction of fluorine into drug structures to block sites of 
metabolism and improve physicochemical properties is well understood.16 In 3a, these fluorine atoms 
also appear to play a role in controlling the N-stereochemistry with the difluoromethylene and the 
adjacent Boc group orientating themselves away from one another in the solid-state. Further exploration 
of the scope of this reaction reveals that it works well for di-, tri- and tetrasubstituted alkenes, and 
tolerates variation in the N-substituent.  In the difluorocarbene addition to (Z)-2d, only a single 
diastereoisomer was produced. This was assigned as 3b on the basis of NOE experiments (see 
Supporting Information), consistent with stereospecific addition across 2d with net retention of the 
olefin geometry (see Supporting Information). To illustrate that differentiation of the nitrogen atoms in 
the 1,1-difluoro-4,5-diazaspiro[2.3]hexanes is feasible, selective removal of the Boc group from 3d was 
achieved using TFA providing 4 in excellent yield (Scheme 3).
CuI (20 mol%) 
DMEDA (40 mol%) 
Cs2CO3 (2 equiv)
DMEDA, THF
2a-g
62-99%
NN
X Y
N
N
H
X
Br Y NN
Boc Boc
CO2Bn
where a: R, R1 = H, X, Y = CO2Et; b: R, R1 = H, X, Y = CO2iPr;
           c: R, R1 = H, X, Y = Boc; d: R = H, R1 = Me, X, Y = Boc;
           e: R, R1 = Me, X, Y = CO2Et; f: R, R1 = Me, X, Y = Boc; 
g: R, R1 = H, X = Cbz, Y = Boc.
2h
R
R1R
R1
1a-g
Scheme 2. Synthesis of 1,1-difluoro-4,5-diazaspiro[2.3]hexanes. 
Scheme 3. Selective deprotection of 4. 
Encouraged by these findings, we examined the reaction of 3-methylene-1,2-diazetidine 2 with 
dichlorocarbene, formed by base induced α-elimination of chloroform.  The method of Makosza et al. 
using triethylbenzylammonium chloride (TEBAC) as phase transfer catalysis was used.17 Moderate to 
good yields of the corresponding 1,1-dichloro-4,5-diazaspiro[2.3]hexanes were realized (Scheme 4). 
However, with one exception (2a), lower yields were observed in comparison to the difluorocarbene 
additions (Scheme 2). For example, 5a was produced in 48% yield compared to 97% for 3a.  In the case 
of 2h bearing an electron-withdrawing group, we were unable to isolate any of the desired addition 
product. Optimization of the reaction time with careful monitoring of product formation by TLC was 
necessary to obtain satisfactory yields in these dichlorocarbene additions. For example, the yield of 5c
could be improved from 42% to 57% by reducing the reaction time from 240 to 75 min.  Again, a single 
diastereomer of 5b was produced through stereospecific addition.  In the case of 5a, single crystal XRD 
was used to confirm the spirocyclic nature of the product.  
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Scheme 4. Synthesis of 1,1-dichloro-4,5-diazaspiro[2.3]hexanes. 
The lower yields witnessed in the dichlorocarbene additions arise from an unexpected ring expansion 
reaction.  For example, in the reaction of 2c with dichlorocarbene, a near equal quantity of ring 
expanded urea 6 was isolated alongside diazaspiro[2.3]hexane 5a (Scheme 5). Formation of the urea
C=O bond presumably arises from dichlorocarbene insertion into the N–N bond, followed by hydrolysis 
of the two labile C–Cl bonds under the aqueous reaction conditions. Although this process is essentially 
unprecedented, we note that Taylor and Davies have reported intramolecular insertion of a rhodium 
carbenoid into the N–N bond of a 1,2-diazetidin-3-one.18 No products derived from carbene insertion 
into the N–N bond without prior addition to the exocyclic double bond were observed. Moreover, 
resubjection of spirocycle 5a to the cyclopropanation conditions led to formation of 6 in 65% yield.  
Combined with the observation that shorter reaction times led to improved yields of the 1,2-dichloro-
4,5-diazaspiro[2.3]hexanes in some instances, these experiments suggest that carbene addition across 
the double bond is the faster process, with further ring expansion of the diazetidine ring occurring in the 
presence of excess dichlorocarbene. Whilst ring expansion is not seen in reactions involving 
difluorocarbene (Scheme 2), indirect access to these products is possible by treatment of 1,1-difluoro-
4,5-diazaspiro[2.3]hexane 3a with dichlorocarbene leading to 7 in 59% yield (Scheme 5). 
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Scheme 5. Further insights into the carbene addition reactions. 
As tetracyanoethylene (TCNE) is known to be an excellent partner for [2+2] cycloadditions, especially 
with electron-rich alkenes,19 we next chose to examine its use for the formation of the ring expanded 
4,5-diazaspiro[3.3]heptanes. Indeed, treatment of 2 with TCNE (1.0-1.5 equiv) in dichloromethane 
provided 4,5-diazaspiro[3.3]heptanes 9a-f in good to excellent yields (Scheme 6).  The chemical 
efficiency of the reaction lowers with increasing steric bulk of the carbamate groups, and with increased 
substitution of the double bond. The solid-state structure of the spirocycles was unambiguously 
established by single crystal X-ray diffraction of 9a (Scheme 6). To our initial surprise, the major 
product 9e formed in 73% yield by reaction of (Z)-2d with TCNE possesses (R,S)-stereochemistry. This 
relative stereochemistry was confirmed by NOE experiments, which indicated that the methyl group is 
located on the same face as the methylene group of the diazetidine ring (see Supporting Information). A 
small quantity of the (R,R)-diastereomer was also produced (crude d.r. = 4:1) but this proved unstable to 
column chromatography. Unlike the carbene additions to (Z)-2d which proceed stereospecifically with 
retention of the olefin geometry in 3b and 5b, (R,S)-9e arises from inversion of configuration with 
respect to the starting alkene. This outcome suggests that the reaction proceeds in a stepwise manner via 
zwitterionic intermediate 8, with subsequent ring closure to (R,S)-9e.20  TCNE reactions with electron-
rich alkenes commonly proceed in this manner.19  Analysis of molecular models indicates that (R,S)-9e
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ring closure of 8.   
Scheme 6. Synthesis of diazaspiro[3.3]heptanes by reaction of 2 with TCNE. 
In conclusion, we have developed a practical and efficient synthesis of a series of 4,5-
diazaspiro[2.3]hexanes and 1,2-diazaspiro[3.3]heptanes by addition reactions of 3-alkylidene-1,2-
diazetidines. Halogenated 4,5-diazaspiro[2.3]hexanes are produced in good to excellent yields by 
concerted carbene additions to the double bond. With dichlorocarbene, a novel ring expansion of the 
four membered diazetidine ring by way of insertion into the N–N bond was also discovered. Using 
TCNE, a homologous series of 1,2-diazaspiro[3.3]heptanes was produced in good yields by highly 
asynchronous [2+2] cycloadditions. Work to explore the potential of these spirocycles in medicinal 
chemistry programs as hexahydropyridazine analogues is ongoing.
EXPERIMENTAL SECTION 
The synthesis of 2a,8 2c,8 2f8 and 2h9 followed published methods. NMR assignments were deduced 
using 2D experiments (COSY, HMBC, and HMQC). 
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Synthesis of hydrazodicarboxylates 1b, 1d and 1e: General Procedure. 
To a solution of the alcohol (1.0 molar equiv) and triphenylphosphine (2.0 molar equiv) in anhydrous 
THF at 0 °C was added the azodicarboxylate (2.0 molar equiv) portionwise. The mixture was allowed to 
warm to room temperature, stirred for the stated period then concentrated in vacuo. Purification by 
column chromatography provided the products as detailed below. 
Di-iso-propyl 1-(2-bromoallyl)hydrazine-1,2-dicarboxylate (1b)  
2-Bromoallyl alcohol (1.56 g, 11.4 mmol), triphenylphosphine (5.98 g, 22.8 mmol) and di-iso-propyl 
azodicarboxylate (4.49 mL, 22.8 mmol) in anhydrous THF (120 mL) were reacted according to the 
general procedure for 24 h. Purification by column chromatography (SiO2, 7:1 petrol/ ethyl acetate) 
provided 1b (2.75 g, 75%) as a white solid: m. p. 68–69 °C; υmax (film)/cm−1 3284, 2964, 1736, 1682; δH
(400 MHz, CDCl3) 6.84–6.42 (1H, br m, NH), 5.85–5.74 (1H, m, CBr=CHH), 5.57 (1H, s, CBr=CHH), 
5.01–4.86 (2H, m, 2 x CH(CH3)2), 4.50–4.13 (2H, m, NCH2CBr), 1.23 (12H, d, J = 6.2 Hz, 4 x CH3); δC
(100 MHz, CDCl3) 155.5 (COO), 155.3 (COO), 128.2 (CH2=CBr), 119.9 (CH2=CBr, rotamer), 119.4 
(CH2=CBr, rotamer), 70.6 (CO2CH(CH3)2), 70.0 (CO2CH(CH3)2), 58.0 (NCH2CBr, rotamer), 57.3 
(NCH2CBr, rotamer), 22.0 (2 x CH3), 21.9 (2 x CH3); MS (ESI+) m/z 345 (M(79Br)Na+), 347 
(M(81Br)Na+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C11H1979BrN2O4Na 345.0420; found 
345.0416.  
Di-tert-butyl (Z)-1-(2-bromo-2-butenyl)hydrazine-1,2-dicarboxylate (1d)
(Z)-2-Bromo-2-buten-1-ol21 (1.92 g, 12.7 mmol), triphenylphosphine (6.66 g, 25.4 mmol) and di-tert-
butyl azodicarboxylate (5.85 g, 25.4 mmol) in anhydrous THF (60 mL) were reacted according to the 
general procedure for 16 h. Purification by column chromatography (SiO2, 6:1 petrol/ ethyl acetate) 
provided 1d (4.63 g, 99%) as a white solid: m. p. 54–58 °C; υmax (neat)/cm−1 3318, 2931, 1712; δH (500 
MHz, CDCl3) 6.34 (1H, br s, NH), 6.01–5.87 (1H, m, CHCH3), 4.31 (2H, br s, NCH2CBr), 1.77 (3H, d, 
J = 6.5 Hz, CHCH3), 1.46 (18H, s, C(CH3)3); δC (125 MHz, CDCl3) 154.9 (COO), 154.7 (COO), 126.9 
(CHCH3, rotamer), 127.6 (CHCH3, rotamer), 123.6 (NCH2CBr), 81.5 (C(CH3)3), 81.3 (C(CH3)3), 58.5 
(NCH2CBr, rotamer), 57.4 (NCH2CBr, rotamer), 28.2 (2 x C(CH3)3), 16.7 (CHCH3); MS (ESI+) m/z 387 
(M(79Br)Na+), 389 (M(81Br)Na+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C14H2579BrN2O4Na 
387.0890; found 387.0889.  
Diethyl 1-(2-bromo-3-methylbut-2-enyl)hydrazine-1,2-dicarboxylate (1e) 
2-Bromo-3-methylbut-2-en-1-ol (1.00 g, 6.06 mmol), triphenylphosphine (3.17 g, 12.1 mmol) and 
diethyl azodicarboxylate (1.96 mL, 12.1 mmol) in anhydrous THF (100 mL) were reacted according to 
the general procedure for 24 h. Purification by column chromatography provided 1e (1.42 g, 73%) as a 
colourless oil: υmax (film)/cm−1 3300, 2986, 1704; δH (400 MHz, CDCl3) 6.68–6.22 (1H, br m, NH), 
4.68–4.42 (2H, m, NCH2CBr), 4.26–4.16 (4H, m, 2 x CO2CH2CH3), 1.92 (3H, s, CBr=C(CH3)(CH3)), 
1.84 (3H, br s, CBr=C(CH3)(CH3)), 1.27 (6H, t, J = 7.1 Hz, 2 x CO2CH2CH3); δC (100 MHz, CDCl3) 
156.0 (COO), 155.4 (COO), 137.0 (CBr=C(CH3)2, rotamer), 136.6 (CBr=C(CH3)2, rotamer), 115.4 
(CBr=C(CH3)2), 62.5 (CO2CH2CH3), 61.9 (CO2CH2CH3), 53.8 (NCH2CBr, rotamer), 53.3 (NCH2CBr, 
rotamer), 25.5 (CBr=C(CH3)(CH3)), 20.4 (CBr=C(CH3)(CH3)), 14.4 (2 x CO2CH2CH3); MS (ESI+) m/z
345 (M(79Br)Na+), 347 (M(81Br)Na+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C11H1979BrN2O4Na 
345.0420; found 345.0425.  
2-Benzyl 1-(tert-butyl) 1-(2-bromoallyl)hydrazine-1,2-dicarboxylate (1g)
To a solution of sodium hydroxide (318 mg, 7.96 mmol) in H2O (40 mL) and CH2Cl2 (40 mL) at 0 °C 
was added tert-butyl 1-(2-bromoallyl)hydrazine-1-carboxylate22 (2.00 g, 7.96 mmol) followed by the 
dropwise addition of benzyl chloroformate (1.14 mL, 7.99 mmol). The reaction was allowed to warm to 
room temperature over 16 h. The solution was diluted with H2O (40 mL) and the organic layer extracted 
with CH2Cl2 (3 x 50 mL), washed with 20% citric acid solution (60 mL), dried over Na2SO4, filtered 
and concentrated in vacuo. Purification by flash column chromatography (SiO2, 4:1 petrol/ ethyl 
acetate) provided 1g (2.65 g, 86%) as a colourless oil: υmax (film/cm−1) 3297, 2934, 1715, 1632, 1499; 
δH (500 MHz, CDCl3) 7.39–7.31 (5H, m, Ar H), 6.67 (1H, m, NH), 6.38 5.79 (1H, m, CHH=CBr), 5.58 
(1H, s, CHH=CBr), 5.17 (2H, s, CH2Ar), 4.45–4.16 (2H, m, NCH2CBr), 1.49 (5H, br s, C(CH3)3, 
rotamer), 1.39 (4H, br s, C(CH3)3, rotamer); δC (125 MHz, CDCl3) 155.9 (COO), 154.6 (COO), 135.6 
(C, Ar), 128.6 (CH, Ar), 128.5 (CH, Ar), 128.4 (CH, Ar), 128.3 (CH2=CBr), 120.0 (CH2=CBr, rotamer), 
119.5 (CH2=CBr, rotamer), 82.7 (C(CH3)3, rotamer), 82.1 (C(CH3)3, rotamer), 67.8 (CH2Ar), 58.3 
(NCH2, rotamer), 56.9 (NCH2, rotamer), 28.2 (C(CH3)3, rotamer), 28.0 (C(CH3)3, rotamer); MS (ESI+) 
m/z 407 (M(79Br)Na+), 409 (M(81Br)Na+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for 
C16H2179BrN2O4Na 407.0577; found 407.0571. 
Synthesis of 3-alkylidene-1,2-diazetidines 2b, 2d, 2e and 2g: General Procedure. 
To a solution of hydrazine 1 (1.0 molar equiv) in anhydrous THF was added copper (I) iodide (CuI) (0.2 
molar equiv), cesium carbonate (Cs2CO3) (2 molar equiv) and N,N′-Dimethylethylenediamine 
(DMEDA) (0.4 molar equiv), and the mixture was heated under reflux until full consumption of the 
starting material. The reaction was cooled to room temperature and filtered through Celite® with ethyl 
acetate. The solution was concentrated, passed through a column of silica, eluting with ethyl acetate, 
dried over MgSO4, filtered, and concentrated in vacuo. Further purification by column chromatography 
provided the products as detailed below. 
Di-iso-propyl 3-methylene-1,2-diazetidine-1,2-dicarboxylate (2b)
1b (821 mg, 2.55 mmol), CuI (97 mg, 0.51 mmol), Cs2CO3 (1.66 g, 5.10 mmol) and DMEDA (108 µL, 
1.02 mmol) in anhydrous THF (20 mL) were reacted according to the general procedure for 16 h. 
Purification by column chromatography (SiO2, 4:1 petrol/ ethyl acetate) provided 2b (567 mg, 92%) as 
a colourless oil: υmax (film)/cm−1 2983, 1717; δH (400 MHz, CDCl3) 5.10–4.94 (3H, m, C=CHH, 2 x 
CH(CH3)2), 4.66–4.63 (2H, m, NCH2), 4.42–4.38 (1H, m, C=CHH), 1.33 (6H, d, J = 6.2 Hz, 
CH(CH3)2), 1.30 (6H, d, J = 6.2 Hz, CH(CH3)2); δC (100 MHz, CDCl3) 160.1 (COO), 154.9 (COO), 
142.4 (C=CH2), 90.1 (C=CH2), 71.03 (CH(CH3)2), 70.97 (CH(CH3)2), 57.5 (NCH2), 21.9 (2 x CH3), 
21.8 (2 x CH3); MS (ESI+) m/z 265 (MNa+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for 
C11H18N2O4Na 265.1159; found 265.1156.  
Di-tert-butyl (Z)-3-(ethylidene)-1,2-diazetidine-1,2-dicarboxylate (2d) 
(Z)-1d (2.00 g, 5.48 mmol), CuI (209 mg, 1.10 mmol), Cs2CO3 (3.58 g, 11.0 mmol) and DMEDA (240 
μL, 2.20 mmol) in anhydrous THF (34 mL) were reacted according to the general procedure for 5 d. 
Purification by column chromatography (SiO2, 10:1 petrol/ ethyl acetate) provided 2d (990 mg, 64%) as 
a white solid: m. p. 80–83 °C; υmax (neat)/cm−1 2981, 2937, 1740; δH (500 MHz, CDCl3) 4.70 (1H, q, J = 
7.2 Hz, CHCH3), 4.58 (2H, s, NCH2), 1.80 (3H, d, J = 7.2 Hz, CHCH3), 1.53 (9H, s, C(CH3)3), 1.50 
(9H, s, C(CH3)3); δC (125 MHz, CDCl3) 159.5 (COO), 155.6 (COO), 135.6 (CCH2), 103.5 (CHCH3), 
82.8 (C(CH3)3), 82.3 (C(CH3)3), 58.0 (CH2), 28.14 (C(CH3)3), 28.07 (C(CH3)3), 12.8 (CHCH3); MS 
(ESI+) m/z 307 (MNa+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C14H24N2O4Na 307.1628; found 
307.1630. 
Diethyl 3-(propan-2-ylidene)-1,2-diazetidine-1,2-dicarboxylate (2e)
1e (870 mg, 2.69 mmol), CuI (118 mg, 0.62 mmol), Cs2CO3 (2.03 g, 6.23 mmol) and DMEDA (132 µL, 
1.24 mmol) in anhydrous THF (20 mL) were reacted according to the general procedure for 16 h. 
Purification by column chromatography (SiO2, 4:1 petrol/ ethyl acetate) provided 2e (610 mg, 94%) as a 
colourless oil: υmax (film)/cm−1 2985, 1710; δH (400 MHz, CDCl3) 4.68 (2H, br s, NCH2), 4.23 (2H, q, J
= 7.1 Hz, CO2CH2CH3), 4.22 (2H, q, J = 7.1 Hz, CO2CH2CH3), 1.77 (3H, m, C=C(CH3)(CH3)), 1.48 
(3H, br s, C=C(CH3)(CH3)), 1.29 (3H, t, J = 7.1 Hz, CO2CH2CH3), 1.27 (3H, t, J = 7.1 Hz, 
CO2CH2CH3); δC (100 MHz, CDCl3) 160.5 (COO), 157.8 (COO), 129.3 (C=C(CH3)2 or C=C(CH3)2), 
113.5 (C=C(CH3)2 or C=C(CH3)2), 62.90 (CO2CH2CH3), 62.86 (CO2CH2CH3), 58.4 (NCH2), 18.6 
(C=C(CH3)(CH3)), 18.4 (C=C(CH3)(CH3)), 14.4 (CO2CH2CH3), 14.3 (CO2CH2CH3); MS (ESI+) m/z
265 (MNa+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C11H18N2O4Na 265.1159; found: 265.1155.  
2-Benzyl 1-(tert-butyl) 3-methylene-1,2-diazetidine-1,2-dicarboxylate (2g) 
1g (108 mg, 0.28 mmol), CuI (11 mg, 58 μmol), Cs2CO3 (182 mg, 0.56 mmol) and DMEDA (12 μL, 
0.11 mmol) in anhydrous THF (8 mL) were reacted according to the general procedure for 3 d. 
Purification by column chromatography (SiO2, 6:1 petrol/ ethyl acetate) provided 2g (53 mg, 62%) as a 
colourless oil: υmax (film)/cm−1 2933, 1736, 1718, 1498; δH (500 MHz, CDCl3) 7.41–7.32 (5H, m, Ar 
H), 5.26 (2H, s, CH2Ar), 4.99–4.94 (1H, m, C=CHH), 4.62 (1H, d, J = 2.2 Hz, NCHH), 4.61 (1H, d, J = 
2.2 Hz, NCHH), 4.43–4.40 (1H, m, C=CHH), 1.45 (9H, s, C(CH3)3); δC (125 MHz, CDCl3) 159.4 
(CO2C(CH3)3), 155.2 (CO2CH2Ar), 142.3 (C=CH2), 135.3 (C, Ar), 128.6 (CH, Ar), 128.4 (CH, Ar), 
128.1 (CH, Ar), 90.6 (C=CH2), 83.0 (C(CH3)3), 68.3 (CH2Ar), 57.5 (NCH2), 27.9 (C(CH3)3); MS (ESI+) 
m/z 327 (MNa+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C16H20N2O4Na 327.1315; found 
327.1315. 
Synthesis of 1,1-difluoro-4,5-diazaspiro[2.3]hexanes 3a-e: General procedure.  
To a sealed tube was added 3-methylene-1,2-diazetidine (1.0 molar equiv) and sodium iodide (0.2 molar 
equiv) in anhydrous THF. Trimethyl(trifluoromethyl)silane (TMSCF3) (2.5 molar equiv) was added, and 
the sealed tube heated at 65 °C until full consumption of the starting material. The reaction was cooled 
to room temperature and concentrated in vacuo. The residue was diluted with diethyl ether (20 mL) and 
washed with H2O (15 mL), saturated aqueous Na2SO3 solution (15 mL), saturated aqueous sodium 
bicarbonate solution (15 mL) and H2O (15 mL). The organic extract was dried over MgSO4, filtered, 
and concentrated in vacuo. Purification by column chromatography provided the products as detailed 
below.
Di-tert-butyl 1,1-difluoro-4,5-diazaspiro[2.3]hexane-4,5-dicarboxylate (3a)
1,2-Diazetidine 2c (90 mg, 0.33 mmol), sodium iodide (10 mg, 67 μmol) and TMSCF3 (123 μL, 0.83 
mmol) in anhydrous THF (3 mL) were reacted according to the general procedure for 5 h. Purification 
by flash column chromatography (SiO2, 5:1 petrol/ ethyl acetate) provided 3a (103 mg, 97%) as a white 
solid: m. p. 96–99 °C; υmax (neat)/cm−1 2974, 2933, 1737; δH (500 MHz, CDCl3) 4.34 (1H, d, J = 8.4 Hz, 
NCHH), 4.22 (1H, dd, J = 8.4, 4.6 Hz, NCHH), 2.65 (1H, ddd, J = 15.0, 10.1, 4.9 Hz, CHHCF2), 1.51 
(9H, s, C(CH3)3), 1.49 (9H, s, C(CH3)3), 1.43 (1H, ddd, J = 15.3, 10.1, 5.2 Hz, CHHCF2); δC (125 MHz, 
CDCl3) 159.5 (COO), 156.8 (COO), 106.9 (dd, JCF = 293.4, 289.9 Hz, CF2), 83.2 (C(CH3)3), 82.8 
(C(CH3)3), 52.5 (NCH2), 50.0 (dd, JCF = 15.8, 9.8 Hz, CCH2), 28.1 (2 x C(CH3)3), 16.7 (t, JCF = 10.6 Hz, 
CCH2); δF (376 MHz, CDCl3) –136.7 (d, JFF = 170 Hz), –142.8 (d, JFF = 169 Hz); MS (ESI+) m/z 343 
(MNa+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C14H22F2N2O4Na 343.1440; found 343.1435. 
(2S*,3S*)-Di-tert-butyl 1,1-difluoro-2-methyl-4,5-diazaspiro[2.3]hexane-4,5-dicarboxylate (3b) 
1,2-Diazetidine 2d (85 mg, 0.30 mmol), sodium iodide (9 mg, 60 μmol) and TMSCF3 (111 μL, 0.75 
mmol) in anhydrous THF (3 mL) were reacted according to the general procedure for 6 h. Purification 
by flash column chromatography (SiO2, 9:1 petrol/ ethyl acetate) provided (2S*,3S*)-3b (80 mg, 80%) 
as a colourless oil: υmax (film)/cm−1 2980, 2936, 1714; δH (400 MHz, CDCl3) 4.31 (1H, d, J = 8.2 Hz, 
NCHH), 3.97 (1H, dd, J = 8.1, 2.7 Hz, NCHH), 1.60–1.51 (1H, m, CHCH3), 1.47 (9H, s, C(CH3)3), 1.46 
(9H, s, C(CH3)3), 1.32 (3H, d, J = 6.7 Hz, CHCH3); δC (125 MHz, CDCl3) 159.3 (COO), 156.2 (COO), 
109.8 (dd, JCF = 304.5, 296.1 Hz, CF2), 83.0 (C(CH3)3), 82.5 (C(CH3)3), 53.1 (dd, JCF = 14.1, 8.1 Hz, 
CCH2), 52.6 (d, JCF = 6.0 Hz, CCH2), 28.1 (C(CH3)3), 27.7 (C(CH3)3), 24.8 (t, JCF = 9.9 Hz, CHCH3), 
5.3 (d, JCF = 4.3 Hz, CHCH3); δF (376 MHz, CDCl3) –125.8 (d, JFF = 167 Hz), –147.9 (d, JFF = 167 Hz); 
MS (ESI+) m/z 357 (MNa+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C15H24F2N2O4Na 357.1596; 
found 357.1598. 
Di-tert-butyl 1,1-difluoro-(2,2-dimethyl)-4,5-diazaspiro[2.3]hexane-4,5-dicarboxylate (3c)
1,2-Diazetidine 2f (90 mg, 0.30 mmol), sodium iodide (9 mg, 60 μmol) and TMSCF3 (111 μL, 0.75 
mmol) in anhydrous THF (3 mL) were reacted according to the general procedure for 5 h. Purification 
by flash column chromatography (SiO2, 9:1 petrol/ ethyl acetate) provided 3c (100 mg, 96%) as a white 
solid: m. p. 85–87 °C; υmax (neat)/cm−1 2980, 2935, 1727; δH (500 MHz, CDCl3) 4.18 (1H, dd, J = 8.3, 
1.9 Hz, NCHH), 3.95 (1H, dd, J = 8.3, 5.4 Hz, NCHH), 1.50 (9H, s, C(CH3)3), 1.48 (9H, s, C(CH3)3), 
1.38 (3H, s, C(CH3)(CH3)), 1.08 (3H, s, C(CH3)(CH3)); δC (125 MHz, CDCl3) 159.3 (COO), 156.5 
(COO), 111.2 (dd, JCF = 309.6, 299.8 Hz, CF2), 83.0 (C(CH3)3), 82.5 (C(CH3)3), 55.6 (dd, JCF = 13.1, 
8.9 Hz, CCH2), 49.4 (d, JCF = 5.9 Hz, CCH2), 28.1 (C(CH3)3), 27.8 (C(CH3)3), 26.2 (t, JCF = 9.9 Hz, 
C(CH3)2), 14.7 (d, JCF = 7.6 Hz, C(CH3)(CH3)), 13.2 (d, JCF = 5.8 Hz, C(CH3)(CH3)); δF (376 MHz, 
CDCl3) –136.4 (d, JFF = 164 Hz), –144.9 (d, JFF = 164 Hz); MS (ESI+) m/z 371 (MNa+); HRMS 
(ESI/TOF-Q) m/z [M + Na]+ calcd for C16H26F2N2O4Na 371.1753; found 371.1751. 
4-Benzyl 5-(tert-butyl) 1,1-difluoro-4,5-diazaspiro[2.3]hexane-4,5-dicarboxylate (3d) 
1,2-Diazetidine 2g (371 mg, 1.22 mmol), sodium iodide (36 mg, 0.24 mmol), TMSCF3 (451 μL, 3.05 
mmol) in anhydrous THF (15 mL) were reacted according to the general procedure for 4 h. Purification 
by flash column chromatography (SiO2, 5:1 petrol/ ethyl acetate) provided 3d (347 mg, 80%) as a 
colourless oil: υmax (film)/cm−1 2931, 1714, 1496; δH (500 MHz, CDCl3) 7.41–7.29 (5H, m, Ar H), 5.27 
(1H, d, J = 12.3 Hz, CHHAr), 5.15 (1H, d, J = 12.3 Hz, CHHAr), 4.37 (1H, d, J = 8.5 Hz, NCHH), 4.27 
(1H, dd, J = 8.5, 4.6 Hz, NCHH), 2.69 (1H, ddd, J = 15.1, 10.3, 4.8 Hz, CHHCF2), 1.45 (9H, s, 
C(CH3)3), 1.44-1.39 (1H, m, CHHCF2); δC (125 MHz, CDCl3) 159.3 (COO), 158.2 (COO), 135.1 (C, 
Ar), 128.6 (CH, Ar), 128.4 (CH, Ar), 128.1 (CH, Ar), 106.6 (dd, JCF = 292.3, 290.3 Hz, CF2), 83.2 
(C(CH3)3), 68.3 (CH2Ar), 52.8 (NCH2), 50.8 (dd, JCF = 16.0, 10.0 Hz, CCF2), 28.0 (C(CH3)3), 16.6 (t, 
JCF = 11.0 Hz, CH2CF2); δF (376 MHz, CDCl3) –137.4 (d, JFF = 170 Hz), –142.8 (d, JFF = 170 Hz); MS 
(ESI+) m/z 377 (MNa+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C17H20F2N2O4Na 377.1283; 
found 377.1287. 
Diethyl 1,1-difluoro-4,5-diazaspiro[2.3]hexane-4,5-dicarboxylate (3e) 
1,2-Diazetidine 2a (56 mg, 0.26 mmol), sodium iodide (8 mg, 53 μmol), TMSCF3 (96 μL, 0.65 mmol) 
in anhydrous THF (3 mL) were reacted according to the general procedure for 6 h. Purification by flash 
column chromatography (SiO2, 4:1 petrol/ ethyl acetate) provided 3e (32 mg, 47%) as a colourless oil: 
υmax (film)/cm−1 2984, 2937, 1713; δH (500 MHz, CDCl3) 4.42 (1H, d, J = 8.4 Hz, NCHH), 4.35 (1H, 
dd, J = 8.5, 4.6 Hz, NCHH), 4.32–4.17 (4H, m, 2 x CH2CH3), 2.72 (1H, ddd, J = 15.2, 10.6, 5.2 Hz, 
CHHCF2), 1.48 (1H, ddd, J = 15.5, 10.6, 5.8 Hz, CHHCF2), 1.33–1.27 (6H, m, 2 x CH2CH3); δC (125 
MHz, CDCl3) 160.6 (COO), 158.2 (COO), 106.6 (dd, JCF = 292.2, 290.3 Hz, CF2), 63.2 (CH2CH3), 63.1 
(CH2CH3), 53.0 (NCH2), 51.0 (dd, JCF = 15.9, 10.1 Hz, CCH2), 16.6 (t, JCF = 11.0 Hz, CH2CF2), 14.33 
(CH2CH3), 14.28 (CH2CH3); δF (376 MHz, CDCl3) –137.5 (d, JFF = 170 Hz), –143.1 (d, JFF = 170 Hz); 
MS (ESI+) m/z 287 (MNa+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C10H14F2N2O4Na 287.0814; 
found 287.0821. 
Benzyl 1,1-difluoro-4,5-diazaspiro[2.3]hexane-4-carboxylate (4) 
To a solution of 3d (82 mg, 0.23 mmol) in anhydrous CH2Cl2 (5 mL) under an atmosphere of nitrogen 
was added trifluoroacetic acid (176 μL, 2.30 mmol) dropwise. The reaction was stirred at room 
temperature for 5 h and then concentrated. The residue was diluted with CH2Cl2 (10 mL), and washed 
with saturated aqueous sodium bicarbonate solution (10 mL) and H2O (10 mL). The aqueous layer was 
washed with CH2Cl2 (10 mL), the organic extracts combined, dried over MgSO4, filtered, and 
concentrated in vacuo to provide 4 (53 mg, 91%) as a yellow oil: υmax (film)/cm−1 3259, 3030, 2962, 
2899, 1709, 1492; δH (400 MHz, CDCl3) 7.38–7.29 (5H, m, Ar H), 5.60 (1H, br s, NH), 5.22 (1H, d, J = 
12.2 Hz, CHHAr), 5.11 (1H, d J = 12.2 Hz, CHHAr), 4.07 (1H, br m, CCHH), 3.87 (1H, br m, CCHH), 
2.67 (1H, br m, CHHCF2), 1.38 (1H, ddd, J = 15.5, 10.1, 5.2 Hz, CHHCF2); δC (125 MHz, CDCl3) 
157.9 (COO), 135.5 (C, Ar), 128.6 (CH, Ar), 128.4 (CH, Ar), 128.3 (CH, Ar), 107.4 (t, JCF = 291.9 Hz, 
CF2), 67.7 (CH2Ar), 53.5 (dd, JCF = 16.2, 9.8 Hz, CCH2), 46.2 (CCH2), 17.2 (t, JCF = 9.4 Hz, CH2CF2); 
δF (376 MHz, CDCl3) –137.7 (d, JFF = 169 Hz), –142.7 (d, JFF = 169 Hz); MS (ESI+) m/z 255 (MH+), 
277 (MNa+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C12H12F2N2O2Na 277.0759; found 
277.0763. 
Synthesis of 1,1-dichloro-4,5-diazaspiro[2.3]hexanes 5a-e: General procedure.  
To a solution of 3-methylene-1,2-diazetidine (1.0 molar equiv) in chloroform was added 
benzyltriethylammonium (TEBAC) (10 mol %) and aqueous NaOH solution (50 wt %) dropwise. The 
reaction was stirred vigorously at room temperature until full consumption of the starting material. The 
solution was neutralized by addition of saturated aqueous NH4Cl solution (20 mL). The mixture was 
extracted with EtOAc (3 x 30 mL) and the combined extracts were dried over MgSO4, filtered, and 
concentrated in vacuo. Purification by column chromatography provided the products as detailed below. 
Di-tert-butyl 1,1-dichloro-4,5-diazaspiro[2.3]hexane-4,5-dicarboxylate (5a) and di-tert-butyl 1,1-
dichloro-5-oxo-4,6-diazaspiro[2.4]heptane-4,6-dicarboxylate (6) 
1,2-Diazetidine 2c (103 mg, 0.38 mmol), TEBAC (9 mg, 39 μmol), aqueous NaOH solution (5 mL, 50 
wt %) in chloroform (10 mL) were reacted according to the general procedure for 3 h. Purification by 
column chromatography (SiO2, 9:1 petrol/ ethyl acetate) provided less polar 5a (64 mg, 48%) as a white 
solid: m. p. 122–125 °C; υmax (neat)/cm−1 3088, 2980, 2934, 1725; δH (500 MHz, CDCl3) 4.41 (1H, d, J
= 8.9 Hz, NCHH), 4.29 (1H, d, J = 8.9 Hz, NCHH), 2.79 (1H, d, J = 9.5 Hz, CHHCCl2), 1.57–1.51 
(10H, m, CHHCCl2, C(CH3)3), 1.49 (9H, s, C(CH3)3); δC (125 MHz, CDCl3) 159.4 (COO), 156.9 
(COO), 83.2 (C(CH3)3), 82.7 (C(CH3)3), 57.4 (CCl2 or CCH2), 56.0 (CCl2 or CCH2), 54.1 (NCH2), 28.1 
(2 x C(CH3)3), 25.6 (CH2Cl2); MS (ESI+) m/z 375 (M(35Cl)Na+), 377 (M(37Cl)Na+); HRMS (ESI/TOF-
Q) m/z [M + Na]+ calcd for C14H2235Cl2N2O4Na 375.0849; found 375.0849. Further elution provided 
more polar 6 (60 mg, 41%) as a white solid: m. p. 124–127 °C; υmax (neat)/cm−1 3110, 2981, 2929, 
1782, 1729, 1366, 1267, 1138, 769; δH (500 MHz, CDCl3) 4.10 (1H, d, J = 11.4 Hz, NCHH), 3.81 (1H, 
d, J = 11.3 Hz, NCHH), 3.36 (1H, d, J = 9.7 Hz, CHHCCl2), 1.67 (1H, d, J = 9.7 Hz, CHHCCl2), 1.55 
(9H, s, C(CH3)3), 1.50 (9H, s, C(CH3)3); δC (125 MHz, CDCl3) 149.7 (C=O), 149.6 (COO), 148.6 
(COO), 84.4 (C(CH3)3), 84.1 (C(CH3)3), 61.6 (CCl2 or CCH2), 46.9 (CCl2 or CCH2), 46.0 (NCH2), 28.1 
(CH2CCl2), 28.0 (C(CH3)3), 27.9 (C(CH3)3); MS (ESI+) m/z 403 (M(35Cl)Na+), 405 (M(37Cl)Na+); 
HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C15H2235Cl2N2O5Na 403.0798; found 403.0800. 
(2S*,3S*)-Di-tert-butyl 1,1-dichloro-2-methyl-4,5-diazaspiro[2.3]hexane-4,5-dicarboxylate (5b) 
1,2-Diazetidine 2d (85 mg, 0.30 mmol), TEBAC (7 mg, 31 μmol) and aqueous NaOH solution (5 mL, 
50 wt %) in chloroform (10 mL) were reacted according to the general procedure for 15 min. 
Purification by flash column chromatography (SiO2, 9:1 petrol/ ethyl acetate) provided (2S*,3S*)-5b (46 
mg, 42%) as a colourless oil: υmax (film)/cm−1 2979, 2934, 1713; δH (500 MHz, CDCl3) 4.32 (1H, d, J = 
8.6 Hz, NCHH), 4.13 (1H, d, J = 8.6 Hz, NCHH), 1.63 (1H, q, J = 6.8 Hz, CHCH3), 1.53 (3H, d, J = 6.7 
Hz, CHCH3), 1.49 (9H, s, C(CH3)3), 1.46 (9H, s, C(CH3)3); δC (125 MHz, CDCl3) 159.4 (COO), 155.6 
(COO), 82.9 (C(CH3)3), 82.5 (C(CH3)3), 63.2 (CCl2 or CCH2), 59.0 (CCl2 or CCH2), 55.0 (CH2), 34.9 
(CHCH3), 28.1 (C(CH3)3), 27.9 (C(CH3)3), 10.7 (CHCH3); MS (ESI+) m/z 389 (M(35Cl)Na+), 391 
(M(37Cl)Na+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C15H2435Cl2N2O4Na 389.1005; found 
389.1004.  
Di-tert-butyl-1,1-dichloro-(2,2-dimethyl)-4,5-diazaspiro[2.3]hexane-4,5-dicarboxylate (5c)  
1,2-Diazetidine 2f (90 mg, 0.30 mmol), TEBAC (7 mg, 31 μmol) and aqueous NaOH solution (5 mL, 
50 wt %) in chloroform (10 mL) were reacted according to the general procedure for 75 min. 
Purification by flash column chromatography (SiO2, 9:1 petrol/ ethyl acetate) provided 5c (65 mg, 57%) 
as a white solid: m. p. 103–106 °C; υmax (neat)/cm−1 2978, 2932, 1715; δH (400 MHz, CDCl3) 4.12 (2H, 
q, J = 8.4 Hz, NCH2), 1.59 (3H, s, C(CH3)(CH3)), 1.50 (9H, C(CH3)3), 1.48 (9H, s, C(CH3)3), 1.16 (3H, 
s, C(CH3)(CH3)); δC (125 MHz, CDCl3) 159.4 (COO), 155.4 (COO), 82.8 (C(CH3)3), 82.5 (C(CH3)3), 
68.7 (CCl2 or CCH2), 62.0 (CCl2 or CCH2), 52.3 (NCH2), 32.4 (C(CH3)2), 28.1 (C(CH3)3), 27.9 
(C(CH3)3), 20.9 (C(CH3)(CH3)), 19.3 (C(CH3)(CH3)); MS (ESI+) m/z 403 (M(35Cl)Na+), 405 
(M(37Cl)Na+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C16H2635Cl2N2O4Na 403.1162; found 
403.1161.  
Diethyl 1,1-dichloro-4,5-diazaspiro[2.3]hexane-4,5-dicarboxylate (5d)
1,2-Diazetidine 2a (75 mg, 0.35 mmol), TEBAC (8 mg, 35 μmol) and aqueous NaOH solution (5 mL, 
50 wt %) in chloroform (10 mL) were reacted according to the general procedure for 6 h. Purification by 
flash column chromatography (SiO2, 4:1 petrol/ ethyl acetate) provided 5d (67 mg, 64%) as a colourless 
oil: υmax (film)/cm−1 3087, 2985, 2924, 1724, 1467; δH (500 MHz, CDCl3) 4.47 (1H, d, J = 9.0 Hz, 
NCHH), 4.38 (1H, d, J = 9.0 Hz, NCHH), 4.33–4.15 (4H, m, 2 x CH2CH3), 2.84 (1H, d, J = 9.7 Hz, 
CHHCCl2), 1.57 (1H, d, J = 9.8 Hz, CHHCCl2), 1.33–1.25 (6H, m, 2 x CH2CH3); δC (125 MHz, CDCl3) 
160.5 (COO), 158.3 (COO), 63.2 (CH2CH3), 63.1 (CH2CH3), 57.2 (CCl2 or CCH2), 56.5 (CCl2 or 
CCH2), 54.5 (NCH2), 25.6 (CH2CCl2), 14.4 (CH2CH3), 14.3 (CH2CH3); MS (ESI+) m/z 319 
(M(35Cl)Na+), 321 (M(37Cl)Na+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd for C10H1435Cl2N2O4Na 
319.0223; found 319.0221. 
Di-tert-butyl 1,1-difluoro-5-oxo-4,6-diazaspiro[2.4]heptane-4,6-dicarboxylate (7)
To 3a (28 mg, 87 μmol) and TEBAC (2 mg, 9 μmol) in chloroform (3 mL) was added aqueous sodium 
hydroxide (1.5 mL, 50 wt%) dropwise. The reaction was stirred vigorously at room temperature for 6 h, 
then neutralized with saturated aqueous NH4Cl solution (10 mL). The mixture was extracted with 
EtOAc (3 x 10 mL) and the combined extracts were dried over MgSO4, filtered, and concentrated in 
vacuo. Purification by column chromatography (SiO2, 4:1 petrol/ ethyl acetate) provided 7 (18 mg, 
59%) as a white solid: m. p. 118–121 °C; υmax (film)/cm−1 3111, 2973, 2934, 1789, 1718; δH (400 MHz, 
CDCl3) 3.87 (1H, d, J = 10.7 Hz, NCHH), 3.69 (1H, dd, J = 10.8, 6.4 Hz, NCHH), 3.21 (1H, ddd, J = 
13.4, 9.9, 5.5 Hz, CHHCF2), 1.54 (9H, s, C(CH3)3), 1.52 (9H, s, C(CH3)3), 1.48–1.44 (1H, m CHHCF2); 
δC (125 MHz, CDCl3) 149.6 (C=O), 149.1 (COO), 148.6 (COO), 108.8 (t, JCF = 294.8 Hz, CF2), 84.5 
(C(CH3)3), 84.0 (C(CH3)3), 43.7 (d, JCF = 6.5 Hz, NCH2), 41.9 (dd, JCF = 10.9, 9.3 Hz, CCF2), 28.0 
(C(CH3)3), 27.9 (C(CH3)3), 18.5 (t, JCF = 10.3 Hz, CH2CF2); δF (376 MHz, CDCl3) –125.8 (d, JFF = 167 
Hz), –147.9 (d, JFF = 167 Hz); MS (ESI+) m/z 371 (MNa+); HRMS (ESI/TOF-Q) m/z [M + Na]+ calcd 
for C15H22F2N2O5Na 371.1389; found 371.1389. 
Synthesis of diazaspiro[3.3]heptanes 9a-f: General procedure 
To a solution of 3-methylene-1,2-diazetidine (1.0 molar equiv) in CH2Cl2 (3 mL) at 0 °C was added 
tetracyanoethylene (TCNE) (1.0 molar equiv). The solution was allowed to warm to room temperature 
until full consumption of the starting material and concentrated in vacuo. Purification provided the 
products as detailed below. 
Di-tert-butyl-5,5,6,6-tetracyano-1,2-diazaspiro[3.3]heptane-1,2-dicarboxylate (9a)
1,2-Diazetidine 2c (50 mg, 0.19 mmol), TCNE (24 mg, 0.19 mmol) and CH2Cl2 (3 mL) were reacted 
according to the general procedure for 16 h. Recrystallization from ethyl acetate provided 9a (52 mg, 
71%) as a white crystalline solid: m.p. 145–146 °C; υmax (neat)/cm−1 2981, 1705; δH (400 MHz, acetone-
d6) 4.88 (1H, d, J = 10.4 Hz, NCHH), 4.62 (1H, d, J = 10.4 Hz, NCHH), 4.51 (1H, d, J = 15.2 Hz, 
CHHC(CN)2), 3.99 (1H, d, J = 15.2 Hz, CHHC(CN)2), 1.55 (9H, s, C(CH3)3), 1.51 (9H, s, C(CH3)3); δC
(100 MHz, acetone-d6) 159.9 (COO), 154.7 (COO), 112.6 (CN), 112.1 (CN), 110.2 (CN), 109.3 (CN), 
84.9 (C(CH3)3), 83.5 (C(CH3)), 70.1 (CCH2 or C(CN)2), 59.6 (NCH2), 50.7 (CCH2 or C(CN)2), 42.2 
(CH2C(CN)2), 32.2 (CH2C(CN)2), 28.2 (C(CH3)3), 28.1 (C(CH3)3); MS (ESI+) m/z 421 (MNa+); HRMS 
(ESI/TOF-Q) m/z [M + Na]+ calcd for C19H22N6O4Na 421.1595; found 421.1593.
Di-iso-propyl 5,5,6,6-tetracyano-1,2-diazaspiro[3.3]heptane-1,2-dicarboxylate (9b)
1,2-Diazetidine 2b (50 mg, 0.21 mmol), TCNE (26 mg, 0.21 mmol) and CH2Cl2 (3 mL) were reacted 
according to the general procedure for 16 h. Recrystallization from ethyl acetate provided 9b (59 mg, 
77%) as a white crystalline solid: m.p. 172–173 °C; υmax (neat)/cm−1 2986, 2365, 1704; δH (400 MHz, 
CD3CN) 5.08 (1H, sep, J = 6.3 Hz, CO2CH(CH3)2), 4.95 (1H, sep, J = 6.3 Hz, CO2CH(CH3)2), 4.53 
(1H, d, J = 10.4 Hz, NCHH), 4.49 (1H, d, J = 10.4 Hz, NCHH), 4.18 (1H, d, J = 15.8 Hz, CHHC(CN)2), 
3.65 (1H, d, J = 15.8 Hz, CHHC(CN)2), 1.33 (6H, dd, J = 8.0, 6.3 Hz, CO2CH(CH3)2), 1.27 (6H, t, J = 
6.4 Hz, CO2CH(CH3)2); δC (100 MHz, CD3CN) 159.3 (2 x COO), 111.2 (CN), 110.8 (CN), 108.5 (CN), 
107.8 (CN), 72.1 (1C, CH(CH3)2), 71.0 (1C, CH(CH3)2), 68.4 (CCH2 or C(CN)2), 57.9 (NCH2), 49.8 
(CCH2 or C(CN)2), 40.5 (CH2C(CN)2), 31.7 (CH2C(CN)2), 20.8 (CH(CH3)(CH3)), 20.74 
(CH(CH3)(CH3)), 20.69 (CH(CH3)(CH3)), 20.62 (CH(CH3)(CH3)); MS (ESI+) m/z 393 (MNa+); HRMS 
(ESI/TOF-Q) m/z [M + Na]+ calcd for C17H18N6O4Na 393.1282; found 393.1284. 
Diethyl 5,5,6,6-tetracyano-1,2-diazaspiro[3.3]heptane-1,2-dicarboxylate (9c) 
1,2-Diazetidine 2a (50 mg, 0.23 mmol), TCNE (30 mg, 0.23 mmol) and CH2Cl2 (3 mL) were reacted 
according to the general procedure for 16 h. Recrystallization from ethyl acetate provided 9c (67 mg, 
84%) as a white crystalline solid: m.p. 184–185 °C; υmax (neat)/cm−1 2985, 1718; δH (400 MHz, 
CD3CN), 4.55 (1H, d, J = 10.2 Hz, NCHH), 4.50 (1H, d, J = 10.3 Hz, NCHH), 4.38–4.12 (5H, m, 
CHHC(CN)2), 2 x CO2CH2CH3), 3.67 (1H, d, J = 16.0 Hz, CHHC(CN)2), 1.31 (3H, t, J = 7.1 Hz, 
CO2CH2CH3), 1.27 (3H, t, J = 7.1 Hz, CO2CH2CH3); δC (100 MHz, CD3CN) 159.1 (COO), 155.2 
(COO), 111.2 (CN), 110.7 (CN), 108.4 (CN), 107.8 (CN), 68.3 (CCH2 or C(CN)2), 63.3 (CO2CH2CH3), 
62.7 (CO2CH2CH3), 57.7 (NCH2), 49.3 (CCH2 or C(CN)2), 40.6 (CH2C(CN)2), 31.4 (CH2C(CN)2), 
13.27 (CO2CH2CH3), 13.25 (CO2CH2CH3); MS (ESI+) m/z 365 (MNa+); HRMS (ESI/TOF-Q) m/z [M + 
Na]+ calcd for C15H14N6O4Na 365.0969; found 365.0967. 
1-Benzyl 2-(tert-butyl) 5,5,6,6-tetracyano-1,2-diazaspiro[3.3]heptane-1,2-dicarboxylate (9d) 
1,2-Diazetidine 2g (50 mg, 0.17 mmol), TCNE (21 mg, 0.17 mmol) and CH2Cl2 (3 mL) were reacted 
according to the general procedure. Additional TCNE (10 mg, 0.08 mmol) was added after 20 h at 0 °C, 
and the reaction warmed to room temperature and stirred for 6 h until completion, then concentrated in 
vacuo. Purification by flash column chromatography (SiO2, 2:1 petrol/ ethyl acetate) provided 9d (71 
mg, 99%) as a white solid: m.p. 149–151 °C; υmax (neat)/cm−1 2988, 1714, 1502; δH (500 MHz, acetone-
d6) 7.48 (2H, d, J = 7.3 Hz, Ar H), 7.43–7.31 (3H, m, Ar H), 5.38 (1H, d, J = 12.5 Hz, CHHAr), 5.25 
(1H, d, J = 12.5 Hz, CHHAr), 4.91 (1H, d, J = 10.4 Hz, NCHH), 4.68 (1H, d, J = 10.4 Hz, NCHH), 4.52 
(1H, d, J = 15.4 Hz, CHHC(CN)2), 4.03 (1H, d, J = 15.4 Hz, CHHC(CN)2), 1.44 (9H, s, C(CH3)3); δC
(125 MHz, acetone-d6) 158.8 (COO), 155.5 (COO), 135.5 (C, Ar), 128.4 (CH, Ar), 128.3 (CH, Ar), 
128.1 (CH, Ar), 111.8 (CN), 111.2 (CN), 109.3 (CN), 108.3 (CN), 82.8 (C(CH3)3), 69.7 (CCH2 or 
C(CN)2), 68.2 (CH2Ar), 58.8 (NCH2), 50.2 (CCH2 or C(CN)2), 40.9 (CH2C(CN)2), 31.7 (CH2C(CN)2), 
27.2 (C(CH3)3); MS (ESI+) m/z 455 (MNa+); Anal. calcd for C22H20N6O4: C, 61.10; H, 4.66; N, 19.43%. 
Found: C, 61.17; H, 4.71; N, 19.05%.   
(3R*,7S*)-Di-tert-butyl 5,5,6,6-tetracyano-7-methyl-1,2-diazaspiro[3.3]heptane-1,2-dicarboxylate (9e)
1,2-Diazetidine 2d (51 mg, 0.18 mmol), TCNE (23 mg, 0.18 mmol) and CH2Cl2 (3 mL) were reacted 
according to the general procedure for 16 h to give a 4:1 mixture of diastereomers. Purification by flash 
column chromatography (SiO2, 5:1 petrol / ethyl acetate) provided the major diastereomer (3R*,7S*)-9e
(54 mg, 73%) as a white solid: m.p. 65–68 °C; υmax (neat)/cm−1 2981, 2937, 1717; δH (500 MHz, 
acetone-d6) 4.94 (1H, d, J = 10.9 Hz, NCHH), 4.80 (1H, q, J = 7.0 Hz, CHCH3), 4.43 (1H, d, J = 10.8 
Hz, NCHH), 1.70 (3H, d, J = 7.1 Hz, CHCH3), 1.55 (9H, s, C(CH3)3), 1.51 (9H, s, C(CH3)3); δC (125 
MHz, acetone-d6) 158.6 (COO), 153.8 (COO), 110.5 (CN), 109.1 (CN), 109.0 (CN), 108.6 (CN), 84.4 
(C(CH3)3), 82.9 (C(CH3)3), 73.2 (CCH2 or C(CN)2), 53.4 (NCH2), 48.4 (CCH2 or C(CN)2), 45.5 
(CHCH3), 37.3 (CHC(CN)2), 27.21 (C(CH3)3), 27.19 (C(CH3)3), 11.4 (CHCH3); MS (ESI+) m/z 435 
(MNa+); Anal. calcd for C20H24N6O4: C, 58.24; H, 5.87; N, 20.38%. Found: C, 58.21; H, 5.91; N, 
20.24%.  
Diethyl 5,5,6,6-tetracyano-7,7-dimethyl-1,2-diazaspiro[3.3]heptane-1,2-dicarboxylate (9f)  
1,2-Diazetidine 2e (50 mg, 0.21 mmol), TCNE (26 mg, 0.21 mmol) and CH2Cl2 (3 mL) were reacted 
according to the general procedure for 16 h. Recrystallization from ethyl acetate provided 9f (30 mg, 
39%) as a white crystalline solid: m.p. 137–138 °C; υmax (neat)/cm−1 2989, 2333, 1727; δH (400 MHz, 
CD3CN) 4.46 (1H, d, J = 10.5 Hz, NCHH), 4.44–4.35 (2H, m, NCHH, CO2CHHCH3), 4.28-4.17 (3H, 
m, CO2CHHCH3, CO2CH2CH3), 1.68 (3H, s, C(CH3)(CH3)), 1.60 (3H, s, C(CH3)(CH3)), 1.32 (3H, t, J = 
7.1 Hz, CO2CH2CH3), 1.27 (3H, t, J = 7.1 Hz, CO2CH2CH3); δC (100 MHz, CD3CN) 159.2 (COO), 
153.8 (COO), 109.8 (CN), 109.5 (CN), 109.1 (CN), 107.3 (CN), 76.3 (C), 63.0 (CO2CH2CH3), 62.9 
(CO2CH2CH3), 53.9 (NCH2), 53.1 (C), 45.2 (C), 24.2 (C(CH3)(CH3)), 20.9 (C(CH3)(CH3)), 13.22 
(CO2CH2CH3), 13.18 (CO2CH2CH3), one quaternary carbon not observed; MS (ESI+) m/z 393 (MNa+); 
HRMS (ESI/TOF-Q) m/z [M + H]+ calcd for C17H19N6O4 371.1462; found 371.1465.  
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